MarketPulse

Demodex blepharitis

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Tarsus Pharmaceuticals Accelerates XDEMVY Growth, Eyes $670M-$700M 2026 Sales

Tarsus reports Q1 2026 XDEMVY sales exceeding $145M, up 85% YoY, while maintaining full-year guidance of $670M-$700M.
TARSinvestor conferencesQ1 2026 earnings
The Motley FoolThe Motley Fool··Jonathan Ponciano

Tarsus Pharma Rallies 20% Despite CHRO's $839K Share Sale

Tarsus Pharma stock surges 20% as insider sells shares for tax withholding. Strong XDEMVY sales growth and improving margins offset insider transaction.
TARSpipeline expansioninsider sale